Skip to main content
GLOW: Ibrutinib+venetoclax shines in first line for CLL/SLL
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
GLOW: Ibrutinib+venetoclax shines in first line for CLL/SLL
User login
Username
Password
Reset your password
Concept
Lead
score
Chronic Lymphocytic Leukemia
1
1
Brachial
0
0.91
Non-Hodgkin Lymphoma (NHL)
0
0.25
Blood
0
0.21
Biologic Therapy
0
0.16
Residual Disease
0
0.16
Bone Marrow
0
0.15
B-Cell Lymphoma
0
0.11
Bone
0
0.11
Cancer
0
0.11
Lymphoma
0
0.11
Metastasis
0
0.11
Remission
0
0.11
Antineoplastic Drug
0
0.09
Atrial Fibrillation
0
0.09
Tumor Lysis Syndrome
0
0.08
Academia
0
0.05
Europe
0
0.05
Hematology
0
0.05
Immunoglobulin A (IgA)
0
0.05
Infestations
0
0.05
Leukemia
0
0.05
Monoclonal Antibody
0
0.05
New York
0
0.05
Tissue
0
0.05
Travel Medicine
0
0.05
Tumor
0
0.05
Specialty
Lead
score
Hematology-Oncology
1
1
Internal Medicine
0
1
Family Medicine/Primary Care
0
0.41
Pharmacist
0
0.39
Infectious Diseases
0
0.27
Public Health & Prevention
0
0.16
Allergy & Clinical Immunology
0
0.15
Cardiology
0
0.09